$GOSS has received 7 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on August 16, 2025. @adamfeuerstein leads with 3 mentions, while @microcapclub contributes 4 mentions. The most recent discussion centers on Gossamer Bio's pulmonary arterial hypertension (PAH) study results released in late February 2026. @adamfeuerstein posted multiple analyses of the clinical data, highlighting that seralutinib achieved only a 13-meter improvement in six-minute walk distance versus placebo, which was not statistically significant. The voice also noted concerning subgroup analysis results, with one-third of PAH patients expected to benefit showing only a 5-meter difference.